钙离子敏感受体激动剂治疗血液透析患者继发性甲状旁腺功能亢进的效果研究

Study on the Effect of Calcium Ion Sensitive Receptor Agonists in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients

研究钙离子敏感受体激动剂治疗血液透析患者继发性甲状旁腺功能亢进的效果。选取2021年10月-2022年10月宣城市人民医院血液透析科收治的60例维持性血液透析(≥3个月)伴继发性甲状旁腺功能亢进的患者为研究对象,采用随机数字表法将其分为对照组(n=30)和观察组(n=30)两组。对照组行常规活性维生素D(阿法骨化醇)治疗,观察组在对照组基础上行西那卡塞治疗,比较两组患者治疗效果。结果显示,治疗后,观察组血钙含量和iPTH水平显著低于对照组(P<0.05);观察组治疗总有效率显著高于对照组(P<0.05);观察组不良反应发生率低于对照组(P<0.05)。研究发现,钙离子敏感受体激动剂(西那卡塞)治疗维持性血液透析伴继发性甲状旁腺功能亢进患者可以有效降低机体iPTH水平,对钙磷、骨代谢、贫血情况及肾功能影响较小,有较为显著的临床疗效,治疗安全性较高。

Study the effect of calcium ion sensitive receptor agonists in the treatment of secondary hyperparathyroidism in hemodialysis patients.Sixty patients with maintenance hemodialysis(≥3 months)and secondary hyperparathyroidism admitted to the Hemodialysis Department of Xuancheng People’s Hospital from October 2021 to October 2022 were selected as the study subjects.They were randomly divided into a control group(n=30)and an observation group(n=30)using a random number table method.The control group received conventional active vitamin D(alfacalcidol)treatment,while the observation group received cinacalcet treatment on the basis of the control group.Compare the treatment outcomes of two groups of patients.The results showed that after treatment,the blood calcium content and iPTH level in the observation group were significantly lower than those in the control group(P<0.05);The total effective rate of the observation group was significantly higher than that of the control group(P<0.05);The incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Research has found that the use of calcium sensitive receptor agonists(cinacalcet)in maintenance hemodialysis patients with secondary hyperparathyroidism can effectively reduce iPTH levels in the body,with minimal impact on calcium and phosphorus,bone metabolism,anemia,and renal function.It has significant clinical efficacy and high treatment safety.